Navigation Links
New approach to anti-anxiety drugs

Researchers have found that lack of a brain protein makes mice notably less anxious and may extend the findings to humans with anxiety disorders. Anxiety is a natural human response to life,// but when it gets out of hand it can inhibit everyday behaviour and cause much suffering. Around 15 million people might have had the necessity for anxiety related treatment. The anti-anxiety drugs have always been very effective in such needy times. The major class is known as the benzodiazepines but these have the drawback of causing sedation that may make it hard to function. They also have the potential to cause addiction. Researchers at the University of North Carolina, and others, now report that they have found a potential new target for anti-anxiety drugs.

They've been looking at mice genetically altered so they don't produce a natural brain protein called protein kinase C. These mice seem to be more sensitive to the brain's own sedative molecules, known as neurosteroids. They are less fearful of heights and open spaces (a test of anxiety in mice). The researchers wonder if creating inhibitors for protein kinase C would be a useful way forward for treating anxiety in humans, providing an alternative to the benzodiazepines.


'"/>




Page: 1

Related medicine news :

1. Fresh approach to TB treatment
2. More signs to an approaching migraine attack
3. Gene enchances radiation therapy - A novel approach to fight cancer
4. Combined modality approach for effective treatment and enhanced survival in bile duct cancer
5. A new approach to vaginal hysterectomy
6. Multi targeted approach required for suicide prevention in adolescents
7. Mathematical approach to asthma
8. Trident approach reduces malaria in HIV patients
9. A Novel approach in Malaria treatment
10. Cancer drugs in development nearly doubled since 1995
11. Cipla holds talks with mining giant to supply AIDS drugs for South African workers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... ... Haute Living, is proud to recognize Dr. Barry M. Weintraub as a prominent ... “the most beautiful women in the world, and the most handsome men, look ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the placement of ... President of North American Capital Sales at HTG Molecular . , ... the commercialization of the HTG EdgeSeq system and associated reagents in North America. , ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: